Syndication and co-investment for institutional venture capital.

Paris-based enterprise AI startup Dust has secured $40 million in Series B funding to accelerate development of its “multiplayer AI” platform designed to enable humans and AI agents to collaborate across enterprise workflows. The round was co-led by Abstract and Sequoia Capital, with participation from Snowflake Ventures and Datadog Ventures. Founded by Gabriel Hubert and Stanislas Polu, Dust is building an enterprise AI operating system where teams and AI agents share the same workspace, organizational context, tools, and workflows in real time. The company says its platform is already used by more than 3,000 organizations globally, with over 300,000 AI agents deployed across customer environments. Unlike traditional “single-player AI” systems focused on individual chat assistants, Dust is positioning itself as infrastructure for coordinated human-agent collaboration across entire organizations. The platform integrates with enterprise systems including Slack, HubSpot, Notion, Snowflake, Gmail, and Google Drive to enable agents and employees to operate from shared live context. Dust says its AI architecture focuses heavily on enterprise governance, observability, and secure orchestration. The company provides granular permissions, audit trails, analytics, and enterprise-grade compliance features including SOC 2 Type II certification and GDPR compliance with EU and US data residency support. According to CEO Gabriel Hubert, the future of enterprise AI will depend less on standalone chatbots and more on systems where AI agents and humans coordinate work together in parallel across organizations. Dust refers to this operational model as “multiplayer AI,” where workflows continuously evolve through shared memory, self-improving agents, and collaborative operational infrastructure. The fresh capital will support expansion of Dust’s enterprise AI infrastructure, self-improving agent systems, orchestration tooling, and large-scale deployment capabilities as companies increasingly move toward agentic AI operations and AI-native enterprise workflows.

Indian edtech and higher education platform Leverage Edu has secured fresh Series D funding as the company accelerates preparations for a future public listing and expands its international student mobility ecosystem. The round saw participation from existing investors including ETS Strategic Capital, Blume Ventures, Tomorrow Capital, Kaizenvest, and several global institutional backers supporting the company’s cross-border education infrastructure ambitions. Founded by Akshay Chaturvedi, Leverage Edu operates a full-stack international higher education platform helping students access university admissions, financial services, visas, test preparation, accommodation, and career support across global education destinations including the US, UK, Canada, Europe, and Australia. The company has increasingly positioned itself as an “international student operating system,” combining AI-powered counseling, application automation, financial products, and university partnerships to streamline the overseas education journey for Indian students. Leverage Edu says it has already supported millions of students across multiple global markets through its platform and advisory ecosystem. According to reports, the fresh capital will support international expansion, AI infrastructure development, student financing products, strategic acquisitions, and operational scaling ahead of its anticipated IPO roadmap. The company has also expanded aggressively into language learning, test prep, employability services, and embedded fintech solutions linked to global education mobility. Leverage Edu joins a growing category of Indian startups building globally integrated education and workforce mobility platforms as international student demand continues rising despite tightening immigration and visa regulations worldwide. Investors are increasingly betting on AI-enabled student infrastructure, global skilling, and education-fintech convergence.

US-Australian neurotechnology company Omniscient Neurotechnology has secured $27.2 million in Series D funding to accelerate commercialization of its AI-enabled brain mapping and precision neuroscience platform. The round was led by I-MED Radiology Network and existing investors, with participation from healthcare technology and medical imaging backers supporting the expansion of AI-driven neurological diagnostics and surgical planning systems. Founded by neurosurgeon Dr. Michael Sughrue, Omniscient Neurotechnology develops advanced brain mapping software that combines artificial intelligence, connectomics, MRI imaging, and large-scale neural network analysis to help surgeons and clinicians better understand functional brain pathways before complex neurological procedures. The company’s flagship platform, Quicktome™, creates highly detailed patient-specific brain connectivity maps designed to improve surgical precision for brain tumor removal, epilepsy treatment, stroke recovery analysis, and other neurological interventions. The technology aims to reduce risks associated with damaging critical cognitive and motor functions during surgery. According to the company, the fresh capital will support FDA-related expansion efforts, commercialization across global hospital systems, AI model advancement, enterprise deployment infrastructure, and broader adoption of precision neuroscience technologies across clinical workflows. Omniscient is increasingly positioning itself at the intersection of AI, neuroimaging, and precision medicine. The funding highlights growing investor interest in AI-powered medical imaging, digital neuroscience, surgical intelligence systems, and precision healthcare infrastructure as hospitals increasingly adopt data-driven clinical decision support technologies.

German-American fusion startup Focused Energy has secured $240 million in Series A funding to accelerate commercialization of laser-driven fusion energy systems aimed at delivering large-scale carbon-free electricity. The round included support from strategic energy, industrial, and deeptech investors alongside major public funding partnerships connected to Germany’s national fusion energy initiatives. Founded by Scott Mercer and Prof. Markus Roth as a spinout from the Technical University of Darmstadt, Focused Energy is developing inertial confinement fusion systems that use high-powered lasers to compress fusion fuel targets and generate controlled fusion reactions. The company’s architecture is inspired by scientific advances achieved at the US National Ignition Facility (NIF), where researchers demonstrated net energy gain from fusion ignition. Focused Energy is working on advanced target manufacturing systems, laser optimization technologies, and high-repetition fusion reactor designs intended to support commercially viable fusion power plants. The startup says its approach could provide stable baseload electricity without long-lived radioactive waste or carbon emissions associated with fossil fuels. The company plans to use the fresh capital to scale engineering operations, expand US and European research facilities, develop fusion fuel target production systems, and accelerate demonstration milestones required for commercial deployment. Germany has increasingly emerged as a major hub for private fusion investment amid Europe’s broader push toward energy independence and next-generation clean energy technologies. Investors globally are pouring billions into fusion startups as AI infrastructure growth, hyperscale data centers, electrification, and industrial decarbonization dramatically increase long-term global energy demand. Fusion is increasingly viewed as one of the few technologies capable of supplying near-limitless clean baseload power at global scale. Focused Energy joins a rapidly expanding group of fusion companies including Commonwealth Fusion Systems, Helion Energy, TAE Technologies, and Marvel Fusion racing to commercialize practical fusion reactors over the coming decade.

Texas-based biotechnology company Secretome Therapeutics has secured $30 million in Series A funding to accelerate development of its lead cardiac cell therapy candidate STM-01 for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM). The round was fully led and financed by RA Capital Management, one of the world’s most influential healthcare and life sciences investment firms. Founded by Vinny Jindal and based in Plano, Secretome Therapeutics is developing regenerative therapies derived from neonatal cardiac progenitor cells (nCPCs). Its lead candidate STM-01 is designed to reduce inflammation, limit fibrosis, and support heart muscle repair in severe cardiomyopathy conditions linked to neuromuscular diseases such as Duchenne muscular dystrophy. The company stated that the fresh capital will support pivotal Phase 2 and Phase 3 clinical development of STM-01, which could potentially become one of the first disease-modifying therapies specifically targeting cardiac complications in Duchenne patients. Cardiomyopathy remains one of the leading causes of mortality among individuals suffering from DMD. As part of the financing, biotechnology veteran David Lubner joined Secretome’s Board of Directors, while RA Capital Partner Matthew Hammond will serve as Board Observer. Lubner previously held senior leadership roles at Ra Pharmaceuticals, Tetraphase Pharmaceuticals, and PharMetrics, and currently serves on multiple biotech company boards including Dyne Therapeutics and Crescent Bio. RA Capital’s investment signals growing institutional confidence in regenerative medicine, cardiac cell therapies, and next-generation biologics addressing rare diseases with major unmet medical needs. The company is also advancing additional nCPC-derived therapies including STM-21 targeting inflammatory and cardiovascular conditions. The funding comes amid renewed investor interest in advanced cell therapies, precision biologics, and regenerative medicine platforms capable of treating chronic degenerative diseases through tissue repair and immune modulation technologies.

Bengaluru-based semiconductor startup C2i Semiconductors has extended its Series A funding round to $16.7 million with participation from TDK Ventures alongside existing investor Peak XV Partners and several semiconductor industry leaders. The company is building next-generation power delivery infrastructure designed specifically for AI data centers and hyperscale computing systems. Founded by Ram Anant, Vikram Gakhar, Preetam Tadeparthy, Dattatreya Suryanarayana, Harsha S. B, and Muthusubramanian N. V., C2i develops software-defined voltage regulator (VR) platforms and intelligent power management systems that optimize electricity flow from the grid all the way to AI processors and GPUs. As AI infrastructure rapidly scales worldwide, power efficiency has emerged as one of the largest bottlenecks for hyperscale data centers. C2i claims its technology can deliver more than 96% power conversion efficiency, reduce processor temperatures by up to 4°C, and potentially save approximately $12 million annually in a 100MW AI data center environment. The company’s proprietary architecture includes the Manas Controller, a software-defined voltage control system, and the Sarayu Power Stage, designed to improve reliability and efficiency for high-current AI accelerator workloads. C2i says its modular architecture can scale for next-generation AI processors projected to require significantly higher power loads over the coming years. TDK Ventures President Nicolas Sauvage described power delivery as one of the “critical thermal and efficiency constraints of the AI era,” highlighting the strategic importance of infrastructure-level semiconductor innovation as global AI compute demand explodes. The fresh capital will support global expansion, product commercialization, silicon validation, and customer deployments across AI data center ecosystems in the US, Taiwan, and international hyperscale markets. C2i expects its first silicon designs to return from fabrication during 2026.